Literature DB >> 23614642

Acute fibrinoid organizing pneumonia after lung transplantation.

Miranda Paraskeva1, Catriona McLean, Samantha Ellis, Michael Bailey, Trevor Williams, Bronwyn Levvey, Gregory I Snell, Glen P Westall.   

Abstract

RATIONALE: The barrier to long-term success after lung transplantation is the development of chronic lung allograft dysfunction. As the experience with lung transplantation accrues, it has become increasingly apparent that not all chronic allograft dysfunction is consistent with the traditionally recognized small-airway histological process of obliterative bronchiolitis (OB).
OBJECTIVES: To identify and describe chronic allograft dysfunction that is not consistent with the well-described bronchiolitis obliterans syndrome and to further characterize a novel histopathological process, acute fibrinoid organizing pneumonia (AFOP), that has led invariably to respiratory decline and death after lung transplantation.
METHODS: We evaluated 194 bilateral lung transplant recipients, identifying 87 individuals who developed chronic allograft dysfunction. They were then classified according to features on spirometry, chest imaging, and histopathological specimens.
MEASUREMENTS AND MAIN RESULTS: Two main phenotypes of chronic allograft dysfunction were identified; 39 (45%) recipients were categorized as having developed OB and 22 (25%) as having AFOP. Survival in those who developed AFOP was significantly worse than in those who developed OB (median time to death 101 vs. 294 d; P = 0.02), with all exhibiting a rapid decline in respiratory function leading to death.
CONCLUSIONS: AFOP is a novel form of chronic allograft dysfunction exhibiting spirometric, radiological, and histopathological characteristics that differentiate it from OB. The further characterization of chronic allograft dysfunction and its heterogeneous manifestations will allow the targeting of clinical and experimental efforts to prevent and treat chronic allograft dysfunction.

Entities:  

Mesh:

Year:  2013        PMID: 23614642     DOI: 10.1164/rccm.201210-1831OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  30 in total

1.  Telomere length in patients with pulmonary fibrosis associated with chronic lung allograft dysfunction and post-lung transplantation survival.

Authors:  Chad A Newton; Julia Kozlitina; Jefferson R Lines; Vaidehi Kaza; Fernando Torres; Christine Kim Garcia
Journal:  J Heart Lung Transplant       Date:  2017-02-04       Impact factor: 10.247

Review 2.  Immunosuppression and allograft rejection following lung transplantation: evidence to date.

Authors:  Gregory I Snell; Glen P Westall; Miranda A Paraskeva
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 3.  Models of Lung Transplant Research: a consensus statement from the National Heart, Lung, and Blood Institute workshop.

Authors:  Vibha N Lama; John A Belperio; Jason D Christie; Souheil El-Chemaly; Michael C Fishbein; Andrew E Gelman; Wayne W Hancock; Shaf Keshavjee; Daniel Kreisel; Victor E Laubach; Mark R Looney; John F McDyer; Thalachallour Mohanakumar; Rebecca A Shilling; Angela Panoskaltsis-Mortari; David S Wilkes; Jerry P Eu; Mark R Nicolls
Journal:  JCI Insight       Date:  2017-05-04

4.  Restrictive allograft syndrome after lung transplantation: new radiological insights.

Authors:  Adriana Dubbeldam; Caroline Barthels; Johan Coolen; Johny A Verschakelen; Stijn E Verleden; Robin Vos; Geert M Verleden; Walter De Wever
Journal:  Eur Radiol       Date:  2016-11-22       Impact factor: 5.315

5.  Exploring the possibilities: airspace disease in the postallogeneic haematopoietic stem cell transplant period.

Authors:  Talal Hilal; Zartash Gul
Journal:  BMJ Case Rep       Date:  2015-10-29

6.  Update in lung transplantation 2013.

Authors:  Jamie L Todd; Jason D Christie; Scott M Palmer
Journal:  Am J Respir Crit Care Med       Date:  2014-07-01       Impact factor: 21.405

Review 7.  Lung transplantation: a treatment option in end-stage lung disease.

Authors:  Marc Hartert; Omer Senbaklavacin; Bernhard Gohrbandt; Berthold M Fischer; Roland Buhl; Christian-Friedrich Vahld
Journal:  Dtsch Arztebl Int       Date:  2014-02-14       Impact factor: 5.594

8.  Validation and Refinement of Chronic Lung Allograft Dysfunction Phenotypes in Bilateral and Single Lung Recipients.

Authors:  Ariss DerHovanessian; Jamie L Todd; Alice Zhang; Ning Li; Aradhna Mayalall; C Ashley Finlen Copeland; Michael Shino; Elizabeth N Pavlisko; W Dean Wallace; Aric Gregson; David J Ross; Rajan Saggar; Joseph P Lynch; John Belperio; Laurie D Snyder; Scott M Palmer; S Sam Weigt
Journal:  Ann Am Thorac Soc       Date:  2016-05

Review 9.  Chronic lung allograft dysfunction phenotypes and treatment.

Authors:  Stijn E Verleden; Robin Vos; Bart M Vanaudenaerde; Geert M Verleden
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

10.  Impact of forced vital capacity loss on survival after the onset of chronic lung allograft dysfunction.

Authors:  Jamie L Todd; Rahil Jain; Elizabeth N Pavlisko; C Ashley Finlen Copeland; John M Reynolds; Laurie D Snyder; Scott M Palmer
Journal:  Am J Respir Crit Care Med       Date:  2014-01-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.